Alphamab Oncology Announces the Study for Ovarian Cancer
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
February 13, 2025
by PR Newswire
Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer
Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE).
December 30, 2024
by PRNewswire
FDA approves new imaging drug to identify ovarian cancer lesions
The US Food and Drug Administration (FDA) has approved Cytalux (pafolacianine), an imaging drug intended to assist surgeons in identifying ovarian cancer lesions.
December 1, 2021
by EuropeanPharmaceuticalReview
FDA Approves Cytalux
On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent imaging agents to target and illuminate cancer during surgery, today announced that the U.S. Food and Drug Administration (FDA)...
November 30, 2021
by Drugs
FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for Ovarian Cancer Treatment
Alkermes plc announced that the FDA has granted Fast Track designation to nemvaleukin alfa (nemvaleukin), the company's novel, investigational, engineered interleukin-2 (IL-2) variant immunotherapy...
October 28, 2021
by AmericanPharmaceuticalReview
Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer
Sutro Biopharma today announced that the U.S.FDA has granted Fast Track designation for STRO-002, a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC).
August 25, 2021
by drugs
UT Southwestern finds crucial new molecular mechanisms and biomarkers in ovarian cancer
UT Southwestern faculty have discovered what appears to be an Achilles’ heel in ovarian cancers, as well as new biomarkers that could point to which patients are the best candidates for possible new treatments.
August 2, 2021
by firstwordpharma
BDR Pharma launches generic Rucaparib to treat advanced ovarian and prostate cancers
BDR Pharmaceutical launched BDPARIB (Rucaparib) to treat advanced ovarian and prostate cancers.
May 31, 2021
by expresspharma
Verastem Oncology with Breakthrough Therapy for Defactinib in Ovarian Cancer
Results of Early Trial Demonstrate 70% Overall Response Rate (ORR) in Patients with KRAS Mutant Tumors, 44% ORR in KRAS Wild-Type Tumors and 52% ORR in All Evaluable Patients with a Favorable Safety Profile.
May 28, 2021
by americanpharmaceuticalreview
BeiGene’s ovarian cancer drug pamiparib gets conditional approval in China
Discovered by BeiGene researchers, pamiparib inhibits both PARP1 and PARP2. It is being developed as a monotherapy and combination therapy for various solid tumours.
May 11, 2021
by pharmaceutical-technology
Alkermes, Merck Enter Clinical Trial and Supply Agreement
To evaluate nemvaleukin alfa in combination with Keytruda in patients with platinum-resistant ovarian cancer.
April 8, 2021
by contractpharma
Anixa Biosciences, Moffitt Cancer Center File IND Application for Ovarian Cancer CAR-T Therapy
Anixa Biosciences announced an IND (Investigational New Drug) application for its ovarian cancer CAR-T (Chimeric Antigen Receptor T-cell) therapy has been filed with the U.S. Food and Drug Administration (FDA).
March 25, 2021
by americanpharmaceuticalreview